Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

dyskinesias/diarré

Länken sparas på Urklipp
Sida 1 från 52 resultat
Aromatic L-amino acid decarboxylase (AADC) deficiency is an autosomal recessive inborn error of metabolism, affecting catecholamines and serotonin biosynthesis. Cardinal signs consist in psychomotor delay, hypotonia, oculogyric crises, dystonia, and extraneurological symptoms. METHODS We present a
Biliary dyskinesia (BD) is a motility disorder of the gallbladder that can result in right upper quadrant (RUQ) pain, nausea, vomiting, and diarrhea. Cholecystectomy is considered the standard of care for BD. Up to 23 per cent of pediatric patients who undergo surgery for BD have persistent symptoms

Gallbladder dyskinesia in children.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE The purpose of this study was to describe clinico-pathological characteristics in a group of children with motility disorders of the gallbladder and correlate the findings with cases receiving surgical treatment for gallstone during the same period. METHODS Retrospective chart analysis of

Biliary dyskinesia: a potentially unrecognized cause of abdominal pain in children.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Biliary dyskinesia is defined as symptomatic biliary colic without cholelithiasis, and is diagnosed during cholescintigraphy by assessing gallbladder emptying with cholecystokinin (CCK) stimulation. Unfortunately, gallbladder emptying is not routinely assessed during cholescintigraphy in pediatric

Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A double-blind controlled study was undertaken to examine the value of phosphatidylcholine as a treatment for tardive dyskinesia (TD) in 19 psychiatric patients. All patients were maintained on their usual psychotropic medication throughout the entire study. In addition, they were given either

46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Study ObjectiveTo evaluate the long-term safety and tolerability of deutetrabenazine in patients with tardive dyskinesia (TD) at 2years.In the 12-week ARM-TD and AIM-TD studies, deutetrabenazine showed clinically significant improvements in Abnormal

[Hemiballismus disclosing cerebral toxoplasmosis and acquired immunodeficiency syndrome].

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
A 33-year-old Saudi woman presented with right hemiballismus of recent onset. Brain CT showed a left thalamo-subthalamic lesion which was thought initially to be a metastasis or a tuberculoma. The presence of severe subacute diarrhea, multiple lymphadenopathies and lymphopenia suggested an acquired
OBJECTIVE We describe a child with severe generalized choreoathetosis and anti-N-methyl-d-aspartate receptor encephalitis after herpes simplex virus type 1 encephalitis. Recent evidence supports an autoimmune trigger for anti-N-methyl-d-aspartate receptor encephalitis following a viral infection.

[Cholagenic diarrhea].

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE To characterize cholagenic diarrhea as a nosological entity with its specific features of etiology, pathogenesis, clinical picture and treatment. METHODS A total of 167 patients with chronic diarrhea (CD) participated in the trial. Of them, 25 patients have undergone resection of the small

Cholinergic medication for neuroleptic-induced tardive dyskinesia.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND Since the 1950's neuroleptic medication has been extensively used to treat people with chronic mental illnesses, such as schizophrenia. These may cause tardive dyskinesia (TD), abnormal, repetitive and involuntary movements, in up to 20% of those using the medication for longer than three

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
AFQ056 is a novel, selective metabotropic glutamate receptor 5 antagonist. This was a 13-week, double-blind, placebo-controlled study. Patients with Parkinson's disease and moderate-to-severe levodopa (l-dopa)-induced dyskinesia who were receiving stable l-dopa/anti-parkinsonian treatment and were

[Differential diagnosis in "undifferentiated" inflammatory diseases and dyskinesias of the large intestine].

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The majority of foreign gastroenterologists have their doubts whether there exist "undifferentiated" colitisis. They consider these to be a variant of the irritable bowel syndrome. We have examined 173 patients. Of these, 67 percent were less than 45 years of age with significant intestinal

Safety Profile of Opicapone in the Management of Parkinson's Disease.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Opicapone is a new catechol O-methyltransferase (COMT) inhibitor indicated for use as adjunct to levodopa therapy in patients with Parkinson's disease (PD) and motor fluctuations.To characterize the safety and tolerability of adjunct opicapone (25 and 50

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The efficacy and safety of two dosages of tolcapone were compared in a 12-week crossover trial involving 118 nonfluctuating patients with PD on a stable dose of levodopa (L-Dopa). At trial onset, all patients received open-label tolcapone 100 mg three times daily for 4 weeks. At week 4, 116 eligible

Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Tolcapone is a catechol-ortho-methyl-tranferase (COMT) inhibitor that increases the L-DOPA half-life and the duration of effect in Parkinson's disease. We investigated the effect of tolcapone on the plasma catecholamine levels. We measured plasma catecholamines 2h after the first daily dose of
Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge